Navigation Links
Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
Date:3/19/2008

REINACH, Switzerland, March 19 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) today reported that it has submitted a New Drug Application (NDA) in an electronic format for intravenous iclaprim for the treatment of complicated Skin and Skin Structure Infections (cSSSI) to the US Food and Drug Administration (FDA). Arpida has requested a Priority designation for the review of the NDA. Iclaprim is a synthetic diaminopyrimidine which exhibits a rapidly bactericidal action against an extended spectrum of pathogens, including multidrug-resistant bacteria.

The iclaprim NDA contains data from 15 clinical studies, including two adequate and well-controlled multinational pivotal Phase III trials (ASSIST-1 and ASSIST-2, in which approximately 1,000 patients were enrolled and treated). Patients enrolled in both Phase III trials exhibited high incidences of methicillin-resistant Staphylococcus aureus (MRSA). In these two independent Phase III trials, intravenous iclaprim achieved the pre-specified primary endpoint. In the studies, iclaprim was well-tolerated with a safety profile which was compatible with treatment of patients with cSSSI.

Dr Paul Hadvary, Head of Development of Arpida Ltd., commented: "We are convinced that iclaprim - if approved - has the properties to become a successful drug in the hospital antibiotics market. In this market there is a clear need for novel therapies, as several of the currently available drugs are faced with reduced efficacy, emerging resistance or worrying side effects."

Dr Khalid Islam, President and CEO of Arpida Ltd. added: "We're very proud of reaching this important milestone. Arpida has successfully progressed iclaprim from an early preclinical stage all the way to regulatory filing. This achievement is a credit to our team at Arpida as well as to our external partners. We look forward to working closely with the FDA on their review of our submission."

In addition to the cSSSI indication, intraveno
'/>"/>

SOURCE Arpida Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida Announces Full Year 2007 Financial Results
2. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
3. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
4. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
5. Arpida-Supported CME Symposium Available Online
6. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
7. Arpida Presents Preclinical Data on AR-2474 at ICAAC
8. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
9. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
10. Arpida Interim Results for six Months to 30 June 2007
11. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... (PRWEB) September 18, 2014 ... urological and interventional radiology products and services, announced ... as cryotherapy and cryoablation) versus external beam radiotherapy ... of the American Urological Association (MAAUA) Annual Meeting ... "Comparing Relative Effectiveness of Cryosurgery and External Beam ...
(Date:9/18/2014)... 18, 2014 ... ) has announced the addition of ... Strategic Business Report" report to ... report analyzes the worldwide markets for ... the following Product Segments: Polymeric Materials, ...
(Date:9/18/2014)... Research and Markets has announced the addition ... report to their offering. The ... and in-depth study on the current state of the ... a basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including development ...
(Date:9/18/2014)... , Sept. 18, 2014  Neogen Corporation (Nasdaq: ... entered into a strategic agreement with Merck Animal Health ... The Igenity Dairy Heifer Program consists ... information on the genetic potential of replacement dairy heifers. ... calf is born, and is an excellent tool in ...
Breaking Biology Technology:HealthTronics Announces Data Comparing Cryotherapy Versus Radiation for Treating Prostate Cancer Poster Presented at the American Urological Association Regional Meeting 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Global Human Albumin Industry Report 2014 2Global Human Albumin Industry Report 2014 3Merck Animal Health to market Neogen's dairy genomic program 2
... Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) will hold ... a.m. EDT to discuss the first quarter 2009 financial results ... Michael P. Tarnok, Interim Chairman and Chief Executive Officer of ... its financial results for this period in a press release ...
... Mass., May 11 Idenix Pharmaceuticals, Inc. (Nasdaq: ... corporate overview at the upcoming Deutsche Bank 2009 Health Care ... at the Intercontinental Hotel, Boston.The live and archived webcast of ... in the Idenix Investor Center at www.idenix.com ...
... Arts AllianceBATON ROUGE, La., May 11 The Pearson ... year in a row, Louisiana State University,s ( LSU ... scholarships and digital arts equipment. The 2009 class of ... to document their experiences and pass them along to ...
Cached Biology Technology:Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT 2Pearson Foundation Supports Incoming LSU Biology Students With 21st Century Learning Tools 2Pearson Foundation Supports Incoming LSU Biology Students With 21st Century Learning Tools 3
(Date:9/18/2014)... USA Miranda, a small, icy moon of Uranus, ... bodies in the solar system. Despite its relatively small ... intense resurfacing that resulted in the formation of at ... regions called coronae. , These coronae are visible ... least 200 km across. Arden corona, the largest, has ...
(Date:9/18/2014)... many times it,s demonstrated, it,s still hard to ... But by using a signaling system called "quorum ... to suit their population. In short, some bacteria ... act accordingly. , Once the population of quorum-sensing ... innocuous to pathogenic, or from unhelpful to helpful. ...
(Date:9/18/2014)... CHANDLER, AZ, Sept. 18, 2014 -- Arizona turned its ... in just a few short months, earning it the first-ever ... , The March of Dimes presented Will Humble, M.P.H., Arizona,s ... ceremony held here today. Mr. Humble established a policy of ... hospitals to send newborn blood samples to the lab for ...
Breaking Biology News(10 mins):Miranda: An icy moon deformed by tidal heating 2Miranda: An icy moon deformed by tidal heating 3Miranda: An icy moon deformed by tidal heating 4Miranda: An icy moon deformed by tidal heating 5Miranda: An icy moon deformed by tidal heating 6Miranda: An icy moon deformed by tidal heating 7Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3
... they had already eaten -- in this case, leftover chicken-wing ... no such environmental cues, finds a new Cornell study. , ... a table where leftover bones accumulated compared with those whose ... women. , "The results suggest that people restrict their ...
... images of past experiences, has been studied extensively for ... been surprisingly little research into cognitive processes underlying another ... clearly imagine or "see" oneself participating in a future ... St. Louis have used advanced brain imaging techniques to ...
... watchman of the genome" for its ability to guard against ... different level of cancer protection: By prompting the skin to ... deters the development of melanoma skin cancer, the fastest-increasing form ... the March 9 issue of the journal Cell, researchers at ...
Cached Biology News:Imaging pinpoints brain regions that 'see the future' 2Imaging pinpoints brain regions that 'see the future' 3Imaging pinpoints brain regions that 'see the future' 4'Guardian of the genome' protein found to underlie skin tanning 2'Guardian of the genome' protein found to underlie skin tanning 3
Mouse monoclonal antibody raised against a partial recombinant SCARB2. NCBI Entrez Gene ID = SCARB2...
...
Mouse polyclonal antibody raised against a partial recombinant CSRP3. NCBI Entrez Gene ID = 8048...
... HDAC8 Regulation of gene expression ... as DNA methylation, ATP-dependent chromatin remodeling, ... which include the dynamic acetylation and ... residues present in the tail of ...
Biology Products: